Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
User experienced severe allergic reactions and liver issues after a hair transplant, likely due to antibiotics and medications. Despite trying Minoxidil, the user faced further complications and is now seeking medical advice for potential future transplants.
A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.
Topical dutasteride residue on pillows may cause ear redness and irritation. The user is concerned about a contact reaction from the treatment transferring to the pillow.
The conversation discusses the difficulty in distinguishing between side effects of finasteride (like brain fog and loss of libido) and depression caused by hair loss. Users share experiences of severe depression while on finasteride, leading some to stop the treatment despite anxiety over hair loss.
The conversation warns about taking information on pyrilutamide with skepticism, suggesting that many may not have the genuine product. It advises to wait for FDA approval for reliable information.
Finasteride is used for hair loss, with mixed reports of no side effects and claims of long-term negative effects known as Post Finasteride Syndrome (PFS). The conversation debates the existence and causes of PFS, with differing opinions on whether it is psychological or real.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
Finasteride and dutasteride can affect sexual function, cognition, and mood. Alternatives like minoxidil, pyrilutamide, and alfatradiol have varied effectiveness and side effects.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
The user took finasteride for a year with no issues until reading negative stories online, which led to experiencing side effects they believe are psychological. They stopped the medication and are seeking advice on recovering faster.
The conversation concludes that finasteride, a 5α-Reductase inhibitor used for hair loss, does not impair cognition either short-term or long-term. It suggests "brain fog" is not caused by the medication.
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.
Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.
User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.
Concerns about hair loss treatments like finasteride and minoxidil not being administered during a coma. Dutasteride remains in the system longer, and hair loss may not be immediate if treatment stops temporarily.
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.
A user reports persistent sexual side effects three months after stopping finasteride, despite a healthy lifestyle and supplements. They express concern over the lack of libido and infrequent erections.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
The user is considering reducing RU58841 dosage from 100mg to 17.5mg for long-term safety due to brain fog issues from finasteride. They apply RU58841 only to the front of the scalp where thinning occurs.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
A 20-year-old male experienced mental fog after resuming topical minoxidil for hair loss, questioning if it's due to interactions with antidepressants. Suggestions included trying a lower concentration of minoxidil or alternatives like copper peptides.
The conversation discusses starting hair loss treatments and concerns about side effects. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.
A user shared progress pictures showing significant hair regrowth after using 1mg finasteride and weekly microneedling for about 2.5 to 3 months. The user reported no side effects and maintained good health and mood.